Metabolic acidosis and osteodystrophic bone disease in predialysis chronic renal failure: effect of calcitriol treatment.
The role of metabolic acidosis on osteodystrophic bone lesions of chronic renal failure has been studied retrospectively in 24 patients, divided into two equal groups of 12, one with normal acid-base equilibrium (group A) and one with metabolic acidosis (group B). The two groups were found to differ significantly in serum levels of BGP (23.7 +/- 18 vs. 42.3 +/- 24 ng/ml, p < 0.02) and in several bone histomorphometric parameters such as osteoid volume (4.5 +/- 3.4 vs. 10.2 +/- 6.6%, p < 0.01), osteoid surface (27.7 +/- 18 vs. 48.4 +/- 19%, p < 0.01), single-labelled surface (7.94 +/- 2.9 vs. 15.8 +/- 9.9%, p < 0.02), mineralizing surface (60.69 +/- 26 vs. 30.89 +/- 15.8%, p < 0.003) and mineralization lag time (56.5 +/- 54 vs. 170.5 +/- 189 days, p < 0.05), with the acidotic group showing excess osteoid and a defect in mineralization. Osteomalacia was found only in the acidotic group, while the only 2 cases of adynamic bone disease (ABD) were in the nonacidotic group. Calcitriol administration, 0.25 micrograms daily for a period of 1 year, in 5 cases in group A and 6 cases in group B induced significant improvement of bone lesions mainly in group A. Two of these patients following treatment acquired the characteristics of ABD. In group B, the response to treatment was very limited, with 5 patients still showing persistence of the histological mixed type of bone disease. In conclusion, metabolic acidosis is accompanied by osteomalacia, pure or mixed variety, and shows a relative resistance to calcitriol administration. Normal acid-base equilibrium is more frequently associated with mild hyperparathyroidism and ABD, spontaneously or as a consequence of calcitriol administration.